

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

IGR-CaP1

RRID:CVCL_A018

Type: Cell Line

Proper Citation

RRID:CVCL_A018

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A018

Proper Citation: RRID:CVCL_A018

Description: Cell line IGR-CaP1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:20974126](#), [PMID:24525428](#), [PMID:27198502](#)

Comments: Karyotypic information: Has lost chromosome Y., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: IGR-CaP1

Synonyms: Institut Gustave Roussy-Carcinoma Pancreas 1

Cross References: cancercellines:CVCL_A018, IARC_TP53:28239, Wikidata:Q54897375

ID: CVCL_A018

Record Creation Time: 20220427T220631+0000

Record Last Update: 20260829T234313+0000

Ratings and Alerts

No rating or validation information has been found for IGR-CaP1.

No alerts have been found for IGR-CaP1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Len-Tayon K, et al. (2024) A vitamin D-based strategy overcomes chemoresistance in prostate cancer. British journal of pharmacology, 181(21), 4279.

Al-Nakouzi N, et al. (2022) Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer. Nature communications, 13(1), 4760.